Published in Bioorg Med Chem Lett on December 25, 2007
Anti-AIDS agents 79. Design, synthesis, molecular modeling and structure-activity relationships of novel dicamphanoyl-2',2'-dimethyldihydropyranochromone (DCP) analogs as potent anti-HIV agents. Bioorg Med Chem (2010) 1.08
Anti-AIDS agents 85. Design, synthesis, and evaluation of 1R,2R-dicamphanoyl-3,3-dimethyldihydropyrano-[2,3-c]xanthen-7(1H)-one (DCX) derivatives as novel anti-HIV agents. Eur J Med Chem (2011) 0.78
Studies toward the total synthesis of pluraflavin A. Chemistry (2014) 0.75
Directed aromatic functionalization in natural-product synthesis: Fredericamycin A, nothapodytine B, and topopyrones B and D. Beilstein J Org Chem (2011) 0.75
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A (2009) 4.19
Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst (2004) 1.84
Design, synthesis and anticancer activities of stilbene-coumarin hybrid compounds: Identification of novel proapoptotic agents. Bioorg Med Chem (2010) 1.63
REST controls self-renewal and tumorigenic competence of human glioblastoma cells. PLoS One (2012) 1.58
Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biol Ther (2008) 1.47
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res (2003) 1.45
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol (2012) 1.36
Gamma-glutamyltransferase, redox regulation and cancer drug resistance. Curr Opin Pharmacol (2007) 1.33
Overview of tumor cell chemoresistance mechanisms. Methods Mol Med (2005) 1.26
A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics (2004) 1.05
RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia (2009) 1.04
Modulation of cell growth and cisplatin sensitivity by membrane gamma-glutamyltransferase in melanoma cells. Eur J Cancer (2006) 1.03
Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med (2011) 1.02
Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem Pharmacol (2009) 1.02
Feasibility and efficacy of percutaneous transcatheter intraarterial chemotherapy with paclitaxel in albumin nanoparticles for advanced squamous-cell carcinoma of the oral cavity, oropharynx, and hypopharynx. J Vasc Interv Radiol (2007) 1.00
Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem Pharmacol (2004) 0.99
Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther (2008) 0.99
Targeting RET for thyroid cancer therapy. Biochem Pharmacol (2008) 0.96
Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors. Expert Opin Ther Targets (2008) 0.96
Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther (2006) 0.96
The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci (2009) 0.96
Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol Cancer Res (2003) 0.94
Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin Cancer Res (2008) 0.93
Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer (2003) 0.93
Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem Pharmacol (2004) 0.93
ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968. Cancer Lett (2009) 0.92
Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity. J Med Chem (2005) 0.92
A novel atypical retinoid endowed with proapoptotic and antitumor activity. J Med Chem (2003) 0.90
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochem Pharmacol (2012) 0.90
Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition. Biochem Pharmacol (2011) 0.89
Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors. Bioorg Med Chem (2010) 0.89
Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochem Pharmacol (2010) 0.88
DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents. Clin Cancer Res (2011) 0.88
Synthesis of (+)-spirolaxine methyl ether. J Org Chem (2006) 0.88
Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. Neoplasia (2008) 0.88
Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol (2006) 0.88
Strategies to improve the efficacy of platinum compounds. Curr Med Chem (2009) 0.87
Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide. J Phys Chem B (2009) 0.87
Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem (2007) 0.87
Synthesis, structure and conformation of partially-modified retro- and retro-inverso psi[NHCH(CF3)]Gly peptides. Chemistry (2003) 0.87
Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol (2007) 0.87
Modulation of cell sensitivity to antitumor agents by targeting survival pathways. Biochem Pharmacol (2010) 0.86
Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies. J Pharmacol Exp Ther (2007) 0.86
Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series. Biochem Pharmacol (2006) 0.86
Taste-guided identification of high potency TRPA1 agonists from Perilla frutescens. Bioorg Med Chem (2008) 0.86
Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. Mol Cancer Ther (2008) 0.86
Magnetic tweezers measurements of the nanomechanical properties of DNA in the presence of drugs. Nucleic Acids Res (2010) 0.85
Role of c-myc protein in hormone refractory prostate carcinoma: cellular response to paclitaxel. Biochem Pharmacol (2004) 0.85
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett (2010) 0.85
ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood (2003) 0.85
Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma. Biomed Res Int (2013) 0.85
Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system. ChemMedChem (2010) 0.85
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968. Eur J Cancer (2008) 0.85
Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine. Clin Cancer Res (2010) 0.84
Thermal stability of the [Fe(SCys)(4)] site in Clostridium pasteurianum rubredoxin: contributions of the local environment and Cys ligand protonation. J Biol Inorg Chem (2001) 0.84
Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis (2004) 0.84
Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem (2008) 0.84
Thiocolchicine-podophyllotoxin conjugates: dynamic libraries based on disulfide exchange reaction. J Org Chem (2006) 0.84
Simultaneous confidence intervals to compare gene expression profiles using ABC transporter TaqMan microfluidic cards. Oncol Rep (2010) 0.84
Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS One (2011) 0.83
Conformationally rigid nucleoside probes help understand the role of sugar pucker and nucleobase orientation in the thrombin-binding aptamer. Nucleic Acids Res (2009) 0.83
Atomic force microscopy study of DNA conformation in the presence of drugs. Eur Biophys J (2010) 0.83
Sensitization of tumor cells by targeting histone deacetylases. Biochem Pharmacol (2011) 0.83
Alkalizing reactions streamline cellular metabolism in acidogenic microorganisms. PLoS One (2010) 0.83
Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res (2002) 0.83
Extra-cellular thiol metabolism in clones of human metastatic melanoma with different gamma-glutamyl transpeptidase expression: implications for cell response to platinum-based drugs. Int J Cancer (2002) 0.83
Electron microscopy analysis of early localization of cisplatin in ovarian carcinoma cells. Ultrastruct Pathol (2002) 0.83
Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. J Immunother (2010) 0.82
Molecular alterations of cells resistant to platinum drugs: role of PKCalpha. Biochim Biophys Acta (2006) 0.82
Synthesis and cytotoxic activity of polyamine analogues of camptothecin. J Med Chem (2006) 0.82
Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. Biochem Pharmacol (2003) 0.82
Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer. Clin Cancer Res (2002) 0.82
Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins. J Pharmacol Exp Ther (2006) 0.82
Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs (2004) 0.82
Biological effects of a new vacuolar-H,-ATPase inhibitor in colon carcinoma cell lines. Ann N Y Acad Sci (2009) 0.82
Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors. Bioorg Med Chem (2011) 0.81
Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. J Immunother (2008) 0.81
Synthesis and cytotoxic activity of substituted luotonin A derivatives. Bioorg Med Chem Lett (2004) 0.81